5 Key Takeaways
-
1
Kidney biopsy and histology remain central to evaluating graft dysfunction, while molecular testing adds information about gene activity in sampled tissue.
-
2
Molecular results do not always establish the cause of injury and should be interpreted with histology, laboratory findings, and clinical history.
-
3
Creatinine changes can reflect rejection, infection, medication toxicity, reduced blood flow, obstruction, or recurrent disease, which may require different treatments.
-
4
Treating nonrejection injury as rejection by increasing immunosuppression could impair infection control, and immunosuppressive therapies carry other risks.
-
5
Blood- and urine-based biomarkers are under investigation for monitoring, but current evidence does not support using them as universal replacements for biopsy.
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
Newsletters
Receive the latest pathologist news, personalities, education, and career development – weekly to your inbox.
